Findings

What do systematic reviews say?

115 questions · 123 findings · 9 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 10.6%GRADE not reported 11 · 8.9%Very low 13 · 10.6%Low 25 · 20.3%Moderate 37 · 30.1%High 24 · 19.5%

Intervention not reported

Number suffering at least one adverse event · vascular dementia, mild‐to‐moderate severity

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
29 studies · 8033 participants
High

Intervention not reported

Number suffering at least one serious adverse event · vascular dementia, mild‐to‐moderate severity

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 900 participants
Low

Intervention not reported

Number suffering agitation as an adverse event · vascular dementia, mild‐to‐moderate severity

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 900 participants
Low

Intervention not reported

Cognitive Function (SIB) · Alzheimer's disease (AD), moderate‐to‐severe

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 3337 participants
High

Intervention not reported

Functional performance on activities of daily living: ADCS‐ADL19 54‐point scale · Alzheimer's disease (AD), moderate‐to‐severe

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 2687 participants
High

Intervention not reported

Behaviour and Mood (NPI) · Alzheimer's disease (AD), moderate‐to‐severe

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 3674 participants
High

Intervention not reported

Binary outcomes · Alzheimer's disease (AD), moderate‐to‐severe

The review found no eligible studies for this question.

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause discontinuation · Alzheimer's disease (AD), moderate‐to‐severe

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 5087 participants
High

Intervention not reported

Number suffering at least one adverse event · Alzheimer's disease (AD), moderate‐to‐severe

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
29 studies · 8033 participants
High

Intervention not reported

Number suffering at least one serious adverse event · Alzheimer's disease (AD), moderate‐to‐severe

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
19 studies · 6482 participants
High

Intervention not reported

Number suffering agitation as an adverse event · Alzheimer's disease (AD), moderate‐to‐severe

1 finding from 1 review

Memantine for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 4395 participants
Moderate

Methylphenidate vs placebo

Change in apathy · Apathy in people with mild‐to‐moderate Alzheimer's disease

2 findings from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 145 participants
Low
Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 85 participants
Low

Modafinil vs placebo

Change in apathy · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Modafinil vs placebo

Adverse Events ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Modafinil vs placebo

Change in NPS ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Modafinil vs placebo

Change in cognition ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Modafinil vs placebo

Change in functional performance · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Modafinil vs placebo

Change in global disease severity ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Modafinil vs placebo

Dropouts ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylphenidate vs placebo

Adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease

Methylphenidate showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
RR 1.28 [0.67, 2.42]
3 studies · 145 participants
Low